Skip to main content

Table 4 Univariate and multivariate analyses for DFS in MM patients

From: The clinical impact of hepatitis C virus infection in Egyptian multiple myeloma patients

Items

Univariate

Multivariate

HR

95% CI

P value

HR

95% CI

P value

HCV status

0.741

0.462, 1.189

0.214

0.797

0.386, 1.645

0.540

Age (≥ 65 vs. < 65)

1.545

0.553, 4.315

0.407

1.782

0.340, 9.337

0.494

Gender (male vs. female)

1.003

0.613, 1.643

0.989

0.986

0.429, 2.262

0.973

ISS stage

0.865

0.615, 1.214

0.406

1.367

0.558, 3.352

0.494

β2m (≥ 3.5 vs. < 3.5 mg/L)

0.941

0.475, 1.863

0.861

0.329

0.057, 1.89

0.213

Albumin (< 3.5 vs ≥ 3.5 g/L)

1.058

0.639, 1.749

0.827

1.282

0.504, 3.262

0.602

Hemoglobin (< 10 vs. ≥ 10 g/dL)

0.592

0.361, 0.970

0.037*

0.604

0.284, 1.287

0.191

Platelets (< 100 vs. ≥ 100 × 109/L)

0.780

0.385, 1.579

0.490

0.784

0.072, 7.763

0.808

Serum calcium (≥ 12 vs. < 12 mg/dL)

3.253

0.767, 13.795

0.110

7.042

1.12, 44.45

0.038*

Serum creatinine (≥ 2.0 vs. < 2.0 mg/dL

1.123

0.534, 2.362

0.760

0.741

0.162, 3.384

0.699

Serum ALT (abnormal vs. normal)

0.973

0.236, 4.003

0.969

--

--

--

Serum AST (abnormal vs. normal)

1.055

0.545, 2.042

0.874

0.472

0.125, 1.782

0.268

Serum T. bil. (abnormal vs. normal)

1.902

1.034, 3.50

0.039*

10.94

2.92, 41.02

< 0.001*

  1. HR hazard ratio, CI confidence interval, HCV hepatitis C virus, β2m beta-2-microglobulin, ISS International Staging System, ALT alanine transaminase, AST aspartate aminotransferase, T.bil total bilirubin
  2. *Significant at p ≤ 0.05